Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Eli Lilly’s Daily The anti-obsity or Forglipron pill seems to be so good to stimulate weight loss and reduce blood sugar in diabetic patients like popular injectable GLP-1 drugs as OzempicAccording to new data from a phase 3 test. The results were announced today at the annual meeting of the American Diabetes Association and published In the New England Journal of Medicine.
Eli Lilly is the manufacturer of successful GLP-1 medication shooting, approved like Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Like Ozempic and Wegovy de Novo Nordisk, the two drugs against the fire of Eli Lilly are injected on a weekly basis. But some patients are afraid of needles or would prefer to withdraw a convenience pill.
“What we see is that efficiency, security and tolerability are really consistent with the best injectable GLP-1s,” said Kenneth Custer, president of Cariometabolic Health in Eli Lilly, from the experimental pill of society. “We think it’s a big problem.” The company plans to request regulatory approval for Orforglipron for weight management by the end of this year and the treatment of type 2 diabetes in 2026.
The 40 -week trial has tested three doses of orforglipron – 3 milligrams, 12 milligrams and 36 milligrams – a placebo in 559 patients with type 2. diabetes. The three doses were effective in reducing blood sugar, while medium and highest doses have shown clinically significant and statistically significant reductions in body weight. The highest dose of Orforglipron led to an average weight loss of 7.9%, or 16 pounds, which is comparable to the amount of weight loss observed over the same period in semaglutide and shooting tests. Eli Lilly studies the pill in a longer study in overweight or obesity to see if weight loss continues.
In the current test, participants took the pill once a day without food or water restriction. Those who were randomly assigned to Orforglipron began the study at a dose of 1 milligram per day and slowly increased the dose at four -week intervals. Current GLP-1 drugs are gradually increased in a dose as well as to minimize potential side effects.
Orforglipron has shown gastrointestinal side effects similar to those of other GLP-1 drugs, the most common being diarrhea, nausea, indigestion and constipation. Between 4 and 8 percent of participants in the different dosage groups abandoned the side effects, while 1% in the placebo group interrupted the study.
An oral version of Sémaglutide, sold under the Rybelsus brand name, has been on the market since 2019 but is not approved for weight management and is not as effective for weight loss as injectable GLP-1. A pill specifically for obesity would give patients more treatment options and potentially make these drugs more accessible.
The pills are generally cheaper to manufacture, and they can be produced in mass more easily, which makes them less subject to the shortage. (GLP-1 injected drugs were in shortage until recently.) Pills can also be transported more easily. Current GLP-1 injector pens must be shipped and stored in a refrigerator to maintain their power. A GLP-1 pill would not need sophisticated distribution and storage to the cold chain, which means that it could be sold in countries that do not have this infrastructure.
“With Orforglipron offering additional advantages such as elimination of strict predosage requirements, a potential lower cost and easier storage, it will be important to see if these characteristics lead to even greater adhesion,” explains Priya Jaisinghani, specialist in diabetes and obesity medicine at Nyu Langone. “Like most chronic therapies, GLP-1 are more effective when used in a coherent way, so a formulation that encourages long-term use could have a significant impact on patient results.”
